Freedom Investment Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-9,877
| Closed | -$1.83M | – | 142 |
|
|
2025
Q2 | $1.83M | Buy |
9,877
+293
| +3% | +$54.5K | 0.15% | 115 |
|
|
2025
Q1 | $2.01M | Sell |
9,584
-2,045
| -18% | -$398K | 0.17% | 108 |
|
|
2024
Q4 | $2.07M | Buy |
11,629
+415
| +4% | +$76.3K | 0.17% | 102 |
|
|
2024
Q3 | $2.21M | Sell |
11,214
-605
| -5% | -$113K | 0.18% | 92 |
|
|
2024
Q2 | $2.03M | Buy |
11,819
+1,464
| +14% | +$243K | 0.17% | 112 |
|
|
2024
Q1 | $1.89M | Buy |
10,355
+1,320
| +15% | +$227K | 0.15% | 131 |
|
|
2023
Q4 | $1.4M | Sell |
9,035
-33
| -0.4% | -$4.81K | 0.11% | 165 |
|
|
2023
Q3 | $1.35M | Buy |
9,068
+148
| +2% | +$21.7K | 0.17% | 141 |
|
|
2023
Q2 | $1.2M | Buy |
8,920
+2,381
| +36% | +$349K | 0.13% | 190 |
|
|
2023
Q1 | $1.04M | Sell |
6,539
-3,019
| -32% | -$462K | 0.12% | 233 |
|
|
2022
Q4 | $1.54M | Sell |
9,558
-1,767
| -16% | -$271K | 0.17% | 151 |
|
|
2022
Q3 | $1.52M | Buy |
11,325
+564
| +5% | +$80.9K | 0.18% | 141 |
|
|
2022
Q2 | $1.65M | Sell |
10,761
-4,116
| -28% | -$629K | 0.18% | 140 |
|
|
2022
Q1 | $2.41M | Buy |
14,877
+2,905
| +24% | +$422K | 0.22% | 109 |
|
|
2021
Q4 | $1.62M | Sell |
11,972
-338
| -3% | -$39.9K | 0.12% | 221 |
|
|
2021
Q3 | $1.33M | Sell |
12,310
-1,631
| -12% | -$186K | 0.1% | 261 |
|
|
2021
Q2 | $1.57M | Sell |
13,941
-166
| -1% | -$18.7K | 0.12% | 214 |
|
|
2021
Q1 | $1.53M | Buy |
14,107
+1,724
| +14% | +$184K | 0.12% | 206 |
|
|
2020
Q4 | $1.33M | Sell |
12,383
-2,136
| -15% | -$205K | 0.15% | 148 |
|
|
2020
Q3 | $1.27M | Buy |
14,519
+1,009
| +7% | +$95K | 0.14% | 148 |
|
|
2020
Q2 | $1.33M | Sell |
13,510
-2,378
| -15% | -$209K | 0.14% | 132 |
|
|
2020
Q1 | $1.47M | Buy |
15,888
+3,954
| +33% | +$337K | 0.13% | 151 |
|
|
2019
Q4 | $1.06M | Sell |
11,934
-516
| -4% | -$42.8K | 0.09% | 200 |
|
|
2019
Q3 | $943K | Sell |
12,450
-286
| -2% | -$19.6K | 0.08% | 221 |
|
|
2019
Q2 | $926K | Sell |
12,736
-425
| -3% | -$33.4K | 0.08% | 231 |
|
|
2019
Q1 | $1.06M | Sell |
13,161
-21,419
| -62% | -$1.75M | 0.09% | 224 |
|
|
2018
Q4 | $3.19M | Sell |
34,580
-1,550
| -4% | -$136K | 0.25% | 64 |
|
|
2018
Q3 | $3.42M | Buy |
36,130
+562
| +2% | +$53.3K | 0.21% | 75 |
|
|
2018
Q2 | $3.29M | Buy |
35,568
+8,316
| +31% | +$812K | 0.2% | 79 |
|
|
2018
Q1 | $2.58M | Sell |
27,252
-4,048
| -13% | -$445K | 0.13% | 122 |
|
|
2017
Q4 | $3.03M | Buy |
31,300
+1,317
| +4% | +$124K | 0.15% | 87 |
|
|
2017
Q3 | $2.66M | Buy |
29,983
+5,453
| +22% | +$415K | 0.15% | 91 |
|
|
2017
Q2 | $1.78M | Buy |
24,530
+4,928
| +25% | +$331K | 0.1% | 150 |
|
|
2017
Q1 | $1.28M | Buy |
19,602
+1,002
| +5% | +$63K | 0.07% | 225 |
|
|
2016
Q4 | $1.17M | Buy |
18,600
+9,148
| +97% | +$558K | 0.07% | 206 |
|
|
2016
Q3 | $596K | Sell |
9,452
-3,219
| -25% | -$208K | 0.04% | 400 |
|
|
2016
Q2 | $784K | Sell |
12,671
-347
| -3% | -$21.1K | 0.05% | 284 |
|
|
2016
Q1 | $744K | Buy |
13,018
+1,471
| +13% | +$82K | 0.05% | 284 |
|
|
2015
Q4 | $684K | Buy |
11,547
+5,342
| +86% | +$308K | 0.05% | 297 |
|
|
2015
Q3 | $214K | Buy |
+6,205
| New | +$404K | 0.02% | 596 |
|
Other funds holding ABBV
Freedom Investment Management's ABBV Position: Q3 2025 in Review
Freedom Investment Management sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 9,877 shares — an estimated $1.83M sold.
Freedom Investment Management first reported a position in ABBV in Q3 2015 and held it in 40 quarters. The position peaked at $3.42M in Q3 2018. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.
- Freedom Investment Management reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
- Freedom Investment Management sold 9,877 AbbVie shares in Q3 2025, an estimated $1.83M.
- Freedom Investment Management first reported a position in AbbVie in Q3 2015 and held it in 40 quarters.
- Freedom Investment Management's AbbVie position peaked at $3.42M in Q3 2018.
- 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.
Based on Freedom Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.